Patients take the lead: rare myositis study puts your voice first
NCT ID NCT07374107
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study asks 700 people with rare myositis diseases (and their caregivers) what research questions matter most to them. Through online surveys and forums, the goal is to create a patient-driven list of priorities to guide future studies and funding. No drugs or treatments are tested—this is about listening to patients to shape science.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help researchers focus on what matters most to patients with rare myositis diseases, potentially guiding future treatments and funding.
- What could go wrong
- This is an observational study that collects opinions, not a treatment trial. It will not directly test any drug or therapy, and its impact depends on whether researchers and funders act on the findings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-SYNTHETASE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
MIHRA Foundation - This is a GLOBAL STUDY
RECRUITINGNew Orleans, Louisiana, 70130, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Can a targeted immune drug calm rare muscle inflammation?
- Engineered immune cells take aim at Hard-to-Treat muscle disease
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
- Engineered immune cells take aim at autoimmune diseases